Chronic Hepatitis B Virus Epidemiology Forecast 2025-2034

The World Health Organization (WHO) estimated that 254 million people were affected by chronic hepatitis B infection in 2022, with nearly 1.2 million new infections occurring annually. It was also reported that hepatitis B caused about 1.1 million deaths, mostly from liver damage (cirrhosis) and hepatocellular carcinoma (primary liver cancer).

Chronic Hepatitis B Virus Epidemiology Forecast Report Coverage

The “Chronic Hepatitis B Virus Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Chronic Hepatitis B Virus. It projects the future incidence and prevalence rates of Chronic Hepatitis B Virus across various populations. The study covers age and type as major determinants of the Chronic Hepatitis B Virus-affected population. The report highlights patterns in the prevalence of Chronic Hepatitis B Virus over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of chronic hepatitis B virus in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Chronic Hepatitis B Virus: Disease Overview

Chronic hepatitis B refers to a long-term infection caused by the hepatitis B virus (HBV), which primarily affects the liver. In this condition, the hepatitis B virus remains in the body for six months or more, causing inflammation and potential liver damage. Common transmission routes of the virus include unprotected sex, sharing needles, and from mother to child during childbirth. Chronic HBV can lead to serious complications, such as cirrhosis (scarring of the liver tissue) and liver cancer.

Chronic Hepatitis B Virus: Treatment Overview

Antiviral treatments are widely used to manage the chronic hepatitis B infection and reduce the risk of complications. Nucleos(t)ide analogs, such as tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and entecavir (ETV), help stop the virus from multiplying and can effectively lower the risk of liver damage. Pegylated interferon (PEG-IFN), a type of immune therapy, is recommended to boost the immune system and reduce HBV levels in the blood. Interferon is typically given as an injection and is often given for a limited period (6-12 months).

Epidemiology

The chronic hepatitis B virus epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for chronic hepatitis B virus by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for chronic hepatitis B virus and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• According to the World Health Organization (WHO), an estimated 254 million people were living with chronic hepatitis B infection in 2022, with 1.2 million new cases occurring annually.
• As per the Hepatitis B Foundation, approximately 1 in 3 people worldwide have been infected with the hepatitis B virus. It is also estimated that around 300 million individuals are chronically infected with the virus.
• In the United States, the highest rates of new hepatitis B virus infections are observed among adults aged 30-59 years.
• About 95% of hepatitis B infections in infants and young children lead to chronic hepatitis, while in adults, less than 5% of cases result in chronic hepatitis B infection.

Country-wise Chronic Hepatitis B Virus Epidemiology

The Chronic Hepatitis B Virus epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of chronic hepatitis B virus varies significantly between countries due to differences in vaccination policies, healthcare infrastructure, public health initiatives, and the prevalence of risk factors such as injection drug use and unprotected sex. It is reported that about 880,000 to 1.89 million people in the United States are chronically infected with the hepatitis B virus.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of chronic hepatitis B virus based on several factors.
• The Chronic Hepatitis B Virus Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of chronic hepatitis B virus are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of chronic hepatitis B virus epidemiology in the 8 major markets?
• What will be the total number of patients with chronic hepatitis B virus across the 8 major markets during the forecast period?
• What was the country-wise prevalence of chronic hepatitis B virus in the 8 major markets in the historical period?
• Which country will have the highest number of chronic hepatitis B virus patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of chronic hepatitis B virus during the forecast period of 2025-2034?
• What are the currently available treatments for chronic hepatitis B virus?
• What are the disease risks, signs, symptoms, and unmet needs of chronic hepatitis B virus?

This product will be delivered within 3-5 business days.